Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker

被引：52

作者：

Danese, S. ^{[1
]}

机构：

[1] IRCCS Gastroenterol, Div Gastroenterol, Ist Clin Humanitas, Viale Manzoni, Milan, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2008年 / 40卷

关键词：

Crohn's disease; Inflammatory bowel disease; Infliximab; Ulcerative colitis;

D O I：

10.1016/S1590-8658(08)60530-7

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) plays a central role in mucosal inflammation and is a key mediator in the inflammatory cascade in both Crohn's disease (CD) and ulcerative colitis (UC). Infliximab, a monoclonal antibody against TNF-alpha has been proved highly effective in the clinical management of both forms of IBD. Aim of this paper is to review the mechanisms of action of infliximab in IBD. (c) 2008 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

引用

页码：S225 / S228

页数：4

共 25 条

[1]

Infliximab downregulates interferon-γ production in activated gut T-lymphocytes from patients with Crohn's disease [J].

Agnholt, J ;

Kaltoft, K .

CYTOKINE, 2001, 15 (04) :212-222

[2]

Tumour necrosis factor and inflammatory bowel disease [J].

Armstrong, AM ;

Gardiner, KR ;

Kirk, SJ ;

Halliday, MI ;

Rowlands, BJ .

BRITISH JOURNAL OF SURGERY, 1997, 84 (08) :1051-1058

[3]

TNF-α blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation:: A novel anti-inflammatory mechanism of infliximab in Crohn's disease [J].

Danese, S ;

Sans, M ;

Scaldaferri, F ;

Sgambato, A ;

Rutella, S ;

Cittadini, A ;

Piqué, JM ;

Panes, J ;

Katz, JA ;

Gasbarrini, A ;

Fiocchi, C .

JOURNAL OF IMMUNOLOGY, 2006, 176 (04) :2617-2624

[4]

Adhesion molecules in inflammatory bowel disease: Therapeutic implications for gut inflammation [J].

Danese, S ;

Semeraro, S ;

Marini, M ;

Roberto, I ;

Armuzzi, A ;

Papa, A ;

Gasbarrini, A .

DIGESTIVE AND LIVER DISEASE, 2005, 37 (11) :811-818

[5]

The CD40/CD40L costimulatory pathway in inflammatory bowel disease [J].

Danese, S ;

Sans, M ;

Fiocchi, C .

GUT, 2004, 53 (07) :1035-1043

[6]

Inflammation and the mucosal microcirculation in inflammatory bowel disease: the ebb and flow [J].

Danese, Silvio .

CURRENT OPINION IN GASTROENTEROLOGY, 2007, 23 (04) :384-389

[7]

Immune regulation by microvascular endothelial cells: Directing innate and adaptive immunity, coagulation, and inflammation [J].

Danese, Silvio ;

Dejana, Elisabetta ;

Fiocchi, Claudio .

JOURNAL OF IMMUNOLOGY, 2007, 178 (10) :6017-6022

[8]

Danese S, 2006, WORLD J GASTROENTERO, V12, P4807

[9]

Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease [J].

Di Sabatino, A ;

Ciccocioppo, R ;

Cinque, B ;

Millimaggi, D ;

Morera, R ;

Ricevuti, L ;

Cifone, MG ;

Corazza, GR .

GUT, 2004, 53 (01) :70-77

[10]

Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease [J].

Di Sabatino, A ;

Ciccocioppo, R ;

Armellini, E ;

Morera, R ;

Ricevuti, L ;

Cazzola, P ;

Fulle, I ;

Corazza, GR .

INFLAMMATORY BOWEL DISEASES, 2004, 10 (05) :573-577

← 1 2 3 →